Last checked at 3 Jun 2024 17:20
European shares kick-off June on a high note in anticipation of ECB rate cut
GSK tumbles as Zantac lawsuits allowed to proceed
*Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Glaxosmithkline Share News (GSK)
GSK Share
Price
GSK Share
News
GSK Share
Chat
GSK Share
Trades10,541
GSK
Live RNS
GSK Share
Charts
GSK Level 2
Console
GSK Live
Share Price
GSK Broker
Ratings
GSK Directors
Deals
GSK Financial
Diary
GSK
Fundamentals
GSK Short
Positions
GSK
Media
Glaxosmithkline Information
Share Price Information for Glaxosmithkline (GSK)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1,599.00
Bid:
1,594.50
Ask:
1,595.50
Change:
-19.00 (-1.17%)
Spread:
1.00 (0.063%)
Open:
1,608.00
High:
1,615.00
Low:
1,575.00
Prev. Close:
1,618.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Sunday share tips: GlaxoSmithKline, African Minerals, WANdisco
Sun, 21st Sep 2014 15:56
Buy shares of GlaxoSmithKline, Questor said in the Sunday Telegraph. China's £297m fine against GSK for corruption is manageable and has lifted the cloud that hung over the company. The shares have underperformed the wider market and are trading on 15.3 times forecast earnings compared with 22 times for the FTSE 350 pharma sector. With US and UK investigations into alleged corruption continuing, GSK is not out of the woods yet but it is not in those governments' interests to disrupt GSK's drug programmes and trigger job cuts so the shares should recover.African Minerals and London Mining have had their shares hammered by the falling price of iron ore and the ebola outbreak in Sierra Leone, Danny Fortson said in the Sunday Times. The Inside the City columnist said London Mining is looking for an investor to avoid being taken over by its banks. A new financing is rumoured this week. The infrastructure London Mining relies on is controlled by African Minerals, whose main backer is Shandong Iron and Steel. Shandong could swoop to consolidate the companies, or Glencore or Vitol might inject cash, Fortson speculated. Whatever happens, shareholders will suffer.Buy shares of Acal, Midas advised in the Mail on Sunday. The company makes electronic components for products ranging from kitchen gadgets, including Nespresso's temperature sensors, to industrial lasers. The company has expansion plans in Europe, where the market is fragmented, and also has opportunities in Asia and the US. The internet of things, which lets appliances talk to each other, will also increase demand for customised electronics. Analysts expect annual profits almost to double to £12m from £6.3m. The best is yet to come, Midas said.Questor in the Sunday Telegraph has removed its "highly speculative" buy recommendation from WANdisco and now says sell the shares. WANdisco writes software that helps companies sift large amounts of data and its products should be in high demand. But it has struggled to convert interest into paying customers at a fast enough rate. First-half losses doubled and issuing new shares is the only thing keeping WANdisco afloat. Cut losses and move on, Questor advised.Please note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only as not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.SF
More News
3 Jun 2024 17:19
Pharma, energy stocks drag London's FTSE 100; ECB rate cut hopes cap losses
FTSE 100 down 0.2%, FTSE 250 up 0.8%
*Read more3 Jun 2024 17:00
LONDON MARKET CLOSE: FTSE 100 down amid shaky start in New York
(Alliance News) - The FTSE 100 in London closed lower on Monday, marking a mixed start to June, with GSK firmly at the bottom of the index.
Read more3 Jun 2024 14:01
GSK immunotherapy bowel cancer drug works for 100% of patients
(Alliance News) - An immunotherapy drug could spare bowel cancer patients the need for surgery and chemotherapy after results showed it was effective in 100% of cases.
Read more3 Jun 2024 11:58
LONDON MARKET MIDDAY: FTSE 100 up, while Labour commits to defence
(Alliance News) - Stock prices in London were up at midday, after data from S&P Global signalled a return to growth for the UK manufacturing sector.
Read more3 Jun 2024 09:08
TOP NEWS: GSK vows to appeal adverse Delaware court ruling on Zantac
(Alliance News) - GSK PLC on Monday said it will appeal a US court ruling that it should face jury trials relating to cases concerning the heartburn drug, Zantac.
Read more3 Jun 2024 08:37
LONDON MARKET OPEN: Stocks up amid slew of manufacturing PMIs
(Alliance News) - Stock prices in London opened higher on Monday, ahead of local purchasing managers index data, and comparative prints from several other major global economies.
Read more3 Jun 2024 08:00
LONDON BRIEFING: FTSE 100 seen up; GSK defends ranitidine cancer claim
(Alliance News) - Stocks in London are set to open higher on Monday, ahead of a data-heavy week, kicked off by a slew of manufacturing purchasing managers' index readings.
Read more3 Jun 2024 07:30
GSK to appeal Delaware ruling on jury trials in Zantac cancer cases
(Sharecast News) - GSK shares were down almost 10% on Monday after a US court ruled that jury trials could hear expert witnesses in 70,000 cases brought by cancer sufferers claiming its Zantac heartburn drug caused their condition.
Read more1 Jun 2024 21:35
Delaware judge lets more than 70,000 Zantac lawsuits go forward
June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.
Read more1 Jun 2024 21:07
Delaware judge lets more than 70,000 Zantac lawsuits go forward
June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.
Read more31 May 2024 17:45
US FDA approves Moderna's RSV vaccine with lower-than-expected efficacy in its label
May 31 (Reuters) - The U.S. Food and Drug Administration approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.
Read more31 May 2024 16:01
US FDA approves Moderna's RSV vaccine, its second marketed product
May 31 (Reuters) - The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.
Read more30 May 2024 20:56
What to know about bird flu in dairy cows and the risk to humans
CHICAGO, May 30 (Reuters) - A third U.S. dairy worker tested positive for bird flu after exposure to infected cows, and was the first to suffer respiratory symptoms, U.S. officials said on Thursday in the latest expansion of the outbreak. Bird flu has been found in dairy cattle in nine states. This second case in a Michigan dairy worker was found through increased testing of people and cows in the state following the April 1 identification of a case in a Texas farm worker. Here's what you need to know about the outbreak.
WHY IS H5N1 OR BIRD FLU A CONCERN?Read more30 May 2024 09:23
LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:
Read more